Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape

Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape

Saved in:

Bibliographic Details
Main Authors:	Jiaxin Zhang, Liang Hong, Wenfei Xu, Xin Zhang, Huina Fu, Xinan Song, Jing Zhao
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349300/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Molecular basis of the urate transporter URAT1 inhibition by gout drugs
by: Yang Suo, et al.
Published: (2025-06-01)

Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs
by: Canrong Wu, et al.
Published: (2025-04-01)

Urate-lowering drugs in the treatment of gout: The unknown about the known
by: T. S. Panevin, et al.
Published: (2021-12-01)

Real-life results of urate-driven pharmacotherapy with three urate lowering drugs in gout: allopurinol, febuxostat and benzbromarone
by: Ioana Hotea, et al.
Published: (2023-08-01)

Associations between lipid-lowering drugs and urate and gout outcomes: a Mendelian randomization study
by: Min Liu, et al.
Published: (2025-01-01)

Is Urate-lowering therapy a prevention of first gout episode?
by: Michał Szczepański, et al.
Published: (2025-07-01)

Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)
by: M. S. Eliseev
Published: (2020-09-01)

Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
by: M. N. Chikina
Published: (2019-01-01)

Impact of urate-lowering therapy on quality of life indicators in patients with gout
by: M. N. Chikina, et al.
Published: (2021-06-01)

Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
by: J. Chen, et al.
Published: (2021-04-01)

Evaluation of continued 2-monthly or annual urate monitoring in gout: an extension of the GoutSMART randomised controlled feasibility trial
by: Philip L. Riches, et al.
Published: (2024-11-01)

How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present
by: Robert T. Keenan, et al.
Published: (2024-12-01)

Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data)
by: M. N. Chikina, et al.
Published: (2021-04-01)

Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1
by: Wenjun Guo, et al.
Published: (2025-02-01)

Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?
by: Edward Roddy, et al.
Published: (2024-11-01)

Prospects of anti-inflammatory and urate-lowering therapy of gout: A vector from the past to the future
by: A. A. Garanin, et al.
Published: (2022-05-01)

Analysis of the Relationship of Serum Ferritin, Urate, and Some Hematological Parameters with Disease Activity in Gout Patients
by: Rana Shamoon Elia, et al.
Published: (2024-03-01)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
by: Maria Antonietta D'Agostino, et al.
Published: (2020-02-01)

Pacific community’s perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients
by: Samuela Ofanoa, et al.
Published: (2025-04-01)

Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study
by: Jae-Bum Jun, et al.
Published: (2025-05-01)

Molecular mechanism of drug inhibition of URAT1
by: Zhuoya Yu, et al.
Published: (2025-07-01)

Adherence to urate-lowering therapy while following the national guidelines for the management of patients with gout (preliminary evidence)
by: M. N. Chikina, et al.
Published: (2020-11-01)

Structural Basis for Inhibition of Urate Reabsorption in URAT1
by: Junping Fan, et al.
Published: (2025-02-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Relationship between tissue stress during gait in healthy volunteers and patterns of urate deposition and bone erosion in gout: a biomechanical computational modelling study
by: Nicola Dalbeth, et al.
Published: (2015-08-01)

Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study)
by: M. S. Eliseev, et al.
Published: (2023-10-01)

Colchicine for acute arthritis attacks prevention in patients with gout during urate-lowering therapy (results of a pilot study)
by: M. S. Eliseev, et al.
Published: (2021-08-01)

Monosodium Urate Crystal Depletion and Bone Erosion Response in Kidney Transplant Recipients With Uncontrolled Gout Treated With Pegloticase: PROTECT Serial Dual-Energy Computed Tomography Findings
by: Nicola Dalbeth, MD, et al.
Published: (2025-06-01)

Factors affecting the frequency of arthritis attacks in patients with gout not receiving urate-lowering therapy (results of a pilot retrospective study)
by: M. S. Eliseev, et al.
Published: (2024-06-01)

Association between coronary monosodium urate deposits at DECT and high-risk coronary plaque phenotypes and other features in gout patients
by: Pietro G. Lacaita, et al.
Published: (2025-08-01)

Patent Landscape for Nanotechnology
by: Alexey Streletskiy, et al.
Published: (2015-09-01)

The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid Symptoms
by: Daniel H. Solomon, et al.
Published: (2025-03-01)

Association of the Q141K polymorphism of the ABCG2 gene with the effectiveness of urate-lowering therapy in patients with gout (a pilot study)
by: M. S. Eliseev, et al.
Published: (2021-12-01)

Solving the mysteries of urate transport: structural insights into GLUT9 and URAT1
by: Mei Wang, et al.
Published: (2024-08-01)

Pharmacokinetics and Ex Vivo Activity of 7-Methylxanthine, an Inhibitor of Monosodium Urate Crystallization
by: Miguel D. Ferrer, et al.
Published: (2025-06-01)

Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study [Corrigendum]
by: Jiang C, et al.
Published: (2025-05-01)

Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies
by: Jutabha P, et al.
Published: (2025-02-01)

Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression
by: Yi-Jen Fang, et al.
Published: (2020-01-01)

Exploring the innovation landscape of ginger: Insights from patent documentation analysis
by: Maima Matin, et al.
Published: (2025-01-01)

Sex-specific DNA methylation associations with circulating urate levels and BCG-induced urate changes
by: Zhaoli Liu, et al.
Published: (2025-07-01)